The past week has seen the resolution of 2 high-profile biosimilar patent infringement cases. In the first, a district court’s ruling was upheld, and in the second, a reference drug sponsor agreed to drop its infringement claims—with prejudice—against a biosimilar developer.
The past week has seen the resolution of 2 high-profile biosimilar patent infringement cases. In the first, a district court’s ruling was upheld, and in the second, a reference drug sponsor agreed to drop its infringement claims—with prejudice—against a biosimilar developer.
Amgen v Apotex
On Monday, the US Court of Appeals for the federal circuit upheld a district court verdict in Amgen v Apotex, in which the court ruled that Apotex did not infringe on Amgen’s patent 8,952,138 (the ‘138 patent), which covers a method of refolding proteins expressed in non-mammalian cells, when it developed its proposed filgrastim and pegfilgrastim biosimilars.
Big Molecule Watch reported that, in Amgen’s October appeal before 3 judges, most of the panel’s questions centered on whether patent infringement in Biologics Price Competition and Innovation Act (BPCIA) litigation can be demonstrated by relying on information in an abbreviated Biologics License Application (aBLA), as Amgen had argued, and whether Apotex should have been allowed to rely in court on arguments that the biosimilar developer had not raised in a timely fashion.
In the November ruling, the appellate court affirmed the court’s ruling that Amgen failed to prove direct infringement on its patents by Apotex. The court’s opinion stated that “…it was not Apotex’s burden to prove non-infringement…It was Amgen’s burden to prove that Apotex’s processes would infringe the ‘138 patent.”
Janssen v Samsung Bioepis
Johnson & Johnson division Janssen has voluntarily dropped its patent suit against biosimilar developer Samsung Bioepis in a lawsuit regarding its infliximab biosimilar, Renflexis. Janssen had filed the suit in May, claiming that Samsung Bioepis had both violated the BPCIA and infringed on 3 patents.
After the Supreme Court’s decision in Amgen v Sandoz, the district court dismissed the claims concerning the BPCIA as moot. Janssen and Samsung Bioepis continued to litigate US patents 7,598,083 and 6,900,056 (both of which cover chemically defined media) and 6,773,600 (which covers the use of a clathrate modifier to promote passage of proteins during nanofiltration).
However, on November 10, the parties filed documents to dismiss the remaining claims of patent infringement. The dismissal was filed with prejudice with respect to claims and defenses related to cell culture and downstream purification processes; thus, Janssen cannot file a future suit against Samsung Bioepis over these particular claims.
“Janssen’s withdrawal of the lawsuit marks a positive step towards improving patient access to biosimilars in the United States,” Mingi Hyun, a Samsung Bioepis spokesperson, told Reuters.
Samsung Bioepis launched Renflexis, the second FDA approved infliximab biosimilar, in the United States in July 2017.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.